Alexion Pharmaceuticals Inc.
352 Knotter Drive
About Alexion Pharmaceuticals Inc.Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.
Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
559 articles with Alexion Pharmaceuticals Inc.
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
First Conference Presentation of Results for ALXN1210 in Patients on Soliris® (Eculizumab) at ASH
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Evercore ISI’s Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 8:45 a.m., ET.
11/12/2018Biopharma companies name new members of their leadership teams. Who made big moves this week?
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisse’s 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET.
Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to company’s growing pipeline
Nine abstracts accepted, including three oral presentations of ALXN1210 Phase 3 PNH data
For the second time in less than one week, Dicerna Pharmaceutical has forged a licensing agreement for its GalXC RNAi technology platform. This time Dicerna and Eli Lilly have struck an agreement to use the platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.
3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase
Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology
Shares of Alexion Pharmaceuticals are up nearly 4 percent in premarket trading after the company announced it has teamed up with Dicerna Pharmaceuticals on the development of an RNAi therapeutic for the treatment of complement-mediated diseases.
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.
Brings in clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn).
Alexion Pharmaceuticals today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 10 a.m., EDT.
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neur...
9/24/2018Soliris® Reduced the Risk of Adjudicated On-Trial Relapse by 94.2% Compared to Placebo (p < 0.0001).
In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some ...
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Alexion Pharmaceuticals today announced that management will present at Morgan Stanley’s 16th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT.